Despite these limitations, the data indicate that radiotherapy administration for oligoprogressive breast cancer may confer an advantage in terms of PFS-AR, especially in patients receiving treatment during the first systemic line in HER2+ and luminal-like disease subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.